Nelson M - Search Results

1

Jones R, Nelson M, Bracchi M, Asboe D, Boffito M. Jones R, et al. Among authors: nelson m. Lancet HIV. 2020 Jun;7(6):e383. doi: 10.1016/S2352-3018(20)30139-9. Epub 2020 May 14. Lancet HIV. 2020. PMID: 32416771 Free PMC article. No abstract available.

2

Pneumothorax in AIDS: case reviews and proposed clinical management.

Asboe D, Fisher M, Nelson MR, Kaplan DK, al-Kattan K, Gazzard BG. Asboe D, et al. Among authors: nelson mr. Genitourin Med. 1996 Aug;72(4):258-60. doi: 10.1136/sti.72.4.258. Genitourin Med. 1996. PMID: 8976829 Free PMC article.

3

Efficacy of a nelfinavir- and nevirapine-containing salvage regimen.

Sullivan AK, Nelson MR, Shaw A, Moyle GJ, Mandalia S, Gazzard BG, Asboe D. Sullivan AK, et al. Among authors: nelson mr. HIV Clin Trials. 2000 Jul-Aug;1(1):7-12. doi: 10.1310/64pf-wk1q-96y5-axjq. HIV Clin Trials. 2000. PMID: 11590484 Clinical Trial.

4

BHIVA guidelines: coinfection with HIV and chronic hepatitis C virus.

Nelson MR, Matthews G, Brook MG, Main J; British HIV Association. Nelson MR, et al. HIV Med. 2003 Oct;4 Suppl 1:52-62. doi: 10.1046/j.1468-1293.4.s1.2.x. HIV Med. 2003. PMID: 14511248 Free article. No abstract available.

5

Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.

Ford J, Boffito M, Wildfire A, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A. Ford J, et al. Among authors: nelson m. Antimicrob Agents Chemother. 2004 Jul;48(7):2388-93. doi: 10.1128/AAC.48.7.2388-2393.2004. Antimicrob Agents Chemother. 2004. PMID: 15215085 Free PMC article. Clinical Trial.

6

Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.

Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Mandalia S, Gazzard B, Pozniak A. Boffito M, et al. Among authors: nelson m. Antivir Ther. 2004 Jun;9(3):423-9. Antivir Ther. 2004. PMID: 15259905 Clinical Trial.

7

Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.

Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Gazzard B, Pozniak A. Boffito M, et al. Among authors: nelson m. J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1376-84. doi: 10.1097/01.qai.0000136060.65716.1a. J Acquir Immune Defic Syndr. 2004. PMID: 15483467

8

Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.

Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, Gazzard B. Jones R, et al. Among authors: nelson m. J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1489-95. doi: 10.1097/01.qai.0000138983.45235.02. J Acquir Immune Defic Syndr. 2004. PMID: 15602127

9

Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.

Boffito M, Back D, Stainsby-Tron M, Hill A, Di Perri G, Moyle G, Nelson M, Tomkins J, Gazzard B, Pozniak A. Boffito M, et al. Among authors: nelson m. Br J Clin Pharmacol. 2005 Jan;59(1):38-42. doi: 10.1111/j.1365-2125.2004.02240.x. Br J Clin Pharmacol. 2005. PMID: 15606438 Free PMC article.

10

A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).

Orkin C, Stebbing J, Nelson M, Bower M, Johnson M, Mandalia S, Jones R, Moyle G, Fisher M, Gazzard B. Orkin C, et al. Among authors: nelson m. J Antimicrob Chemother. 2005 Feb;55(2):246-51. doi: 10.1093/jac/dkh515. Epub 2004 Dec 17. J Antimicrob Chemother. 2005. PMID: 15608053 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,411 results

Search Page